Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Array BioPharma, Inc. (NASDAQ: ARRY).

Full DD Report for ARRY

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARRY)

Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting
BOULDER, Colo. , May 16, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present data from the Phase 3 COLUMBUS trial of encorafenib and binimetinib in advanced BRAF -mutant melanoma in an oral presentation on June 4, 2018 , at the 54 th Annual Meet...
Source: PR Newswire
Date: May, 16 2018 17:17
Free Stock Performance Review on Array BioPharma and Three More Biotech Industry
Stock Research Monitor: ITCI, ARGS, and AUPH LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want a free Stock Review on ARRY sign up now at www.wallstequities.com/registration . On Tuesday, the NASDAQ Composite ended the day at 7,351.63, down 0.81%; the Dow Jones Industrial Average ed...
Source: ACCESSWIRE IA
Date: May, 16 2018 07:05
Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics
Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc...
Source: SeekingAlpha
Date: May, 16 2018 03:55
Wired News - Kitov Pharma Signs Consensi(TM) Commercialization Deal with Changshan Pharma in China
Stock Monitor: Array BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Kitov Pharma Ltd (NASDAQ: KTOV ), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-s...
Source: ACCESSWIRE IA
Date: May, 15 2018 07:00
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Lucky Seven: Achaogen Likely To Bounce Back
The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C...
Source: SeekingAlpha
Date: May, 14 2018 08:19
Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop
Thursday and Friday were eventful days for the Lucky Seven and for biotechnology stocks, in general. It requires portfolio reassessment. First, Some Guidelines Before we begin, I'd like to discuss some additional key points to the purpose of the Lucky Seven portfolio: The goal, for all...
Source: SeekingAlpha
Date: May, 12 2018 00:23
Array BioPharma slips 3% premarket after Roche's unsuccessful late-state CRC study
Array BioPharma (NASDAQ: ARRY ) eases  3%  premarket on increased volume in apparent reaction to the failure of Roche's COTELLIC + TECENTRIQ to beat Bayer's STIVARGA in treatment-resistant advanced colorectal cancer (CRC) in a Phase 3 study. More news on: Array BioPharma Inc., ...
Source: SeekingAlpha
Date: May, 10 2018 09:13
Array Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference
BOULDER, Colo. , May 9, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas . The public is welcome to participate in the confere...
Source: PR Newswire
Date: May, 09 2018 16:05
Array BioPharma's (ARRY) CEO Ron Squarer on Q3 2018 Results - Earnings Call Transcript
Array BioPharma (ARRY) Q3 2018 Earnings Conference Call May 9, 2018 9:00 AM ET Executives Andrea Flynn - Senior Director, Investor Relations and Corporate Communications Ron Squarer - Chief Executive Officer Jason Haddock - Chief Financial Officer Victor Sandor - Chief Medical ...
Source: SeekingAlpha
Date: May, 09 2018 14:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1815.6015.7515.8015.381,597,553
2018-05-1715.6015.7515.8015.381,597,553
2017-06-207.778.358.667.71844,166,716
2017-06-197.557.737.877.503,012,783
2017-06-167.517.527.6157.434,008,025

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-21431,479904,73547.6912Short
2018-05-18252,041400,48562.9339Short
2018-05-17209,713395,58453.0135Short
2018-05-16226,381510,89344.3108Short
2018-05-15345,757569,11260.7538Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARRY.


About Array BioPharma, Inc. (NASDAQ: ARRY)

Logo for Array BioPharma, Inc. (NASDAQ: ARRY)

Not available

 

Contact Information

 

 

Current Management

  • Robert E. Conway / CEO
  • Kevin Koch / President
  • David L. Snitman / COO
  • Michael Carruthers / CFO, Secretary

Current Share Structure

  • Market Cap: $3,122,855,547 - 05/11/2018
  • Issue and Outstanding: 207,636,672 - 01/29/2018

 


Recent Filings from (NASDAQ: ARRY)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 06 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018

 

 


Daily Technical Chart for (NASDAQ: ARRY)

Daily Technical Chart for (NASDAQ: ARRY)


Stay tuned for daily updates and more on (NASDAQ: ARRY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ARRY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARRY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ARRY and does not buy, sell, or trade any shares of ARRY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/